{"disease":{"id":"measles","name":"measles"},"drugs":{"marketed":[{"drug_id":"vaccine-administration","indication_name":"Measles, Mumps, and Rubella","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vaccine Support Cp","generic_name":"Vaccine administration","company_name":"Women and Infants Hospital of Rhode Island","drug_phase":"marketed","molecular_target":"unknown","drug_class":"vaccine","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT06218368","title":"A Tool Kit to Improve Vaccine Confidence in the Philippines","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5400,"lead_sponsor_name":"University of Toronto","has_results":false},{"nct_id":"NCT03870061","title":"Evaluation of an Infant Immunization Encouragement Program in Nigeria","phase":"NA","overall_status":"COMPLETED","enrollment_count":5187,"lead_sponsor_name":"GiveWell","has_results":false},{"nct_id":"NCT01702428","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":5016,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01668745","title":"Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":4559,"lead_sponsor_name":"Bandim Health Project","has_results":false},{"nct_id":"NCT01681992","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4538,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01621802","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4011,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00560755","title":"Safety Study of ProQuad® rHA in Infants (V221-037)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3388,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02158364","title":"Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination","phase":"","overall_status":"COMPLETED","enrollment_count":3331,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05592756","title":"Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed","phase":"","overall_status":"COMPLETED","enrollment_count":2964,"lead_sponsor_name":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","has_results":false},{"nct_id":"NCT04899765","title":"Measles and BCG Vaccines for Mother and Child","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Bandim Health Project","has_results":false},{"nct_id":"NCT04177485","title":"Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda","phase":"NA","overall_status":"COMPLETED","enrollment_count":1962,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT00578175","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1851,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00326183","title":"Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02184572","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1742,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00566527","title":"Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1620,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06815835","title":"Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1530,"lead_sponsor_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","has_results":false},{"nct_id":"NCT01536405","title":"Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1412,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT00861744","title":"Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1259,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT07406360","title":"A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1209,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT06399003","title":"Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Shanghai Institute Of Biological Products","has_results":false},{"nct_id":"NCT00092430","title":"Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04013516","title":"Measles Vaccination Cash Incentives Experimental Evidence From Nigeria","phase":"NA","overall_status":"COMPLETED","enrollment_count":1088,"lead_sponsor_name":"IDinsight","has_results":false},{"nct_id":"NCT02058563","title":"Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":996,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00432042","title":"Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":955,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04398706","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":852,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT07112846","title":"Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":830,"lead_sponsor_name":"Hospital Israelita Albert Einstein","has_results":false},{"nct_id":"NCT05630846","title":"A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":801,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00432523","title":"Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":752,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT01506193","title":"Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":716,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03071575","title":"Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":637,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":true},{"nct_id":"NCT02880865","title":"Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":628,"lead_sponsor_name":"PATH","has_results":true},{"nct_id":"NCT07338851","title":"the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"China National Biotec Group Company Limited","has_results":false},{"nct_id":"NCT04183114","title":"Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":540,"lead_sponsor_name":"PT Bio Farma","has_results":false},{"nct_id":"NCT02904642","title":"Mobile and Scalable Innovations for Measles Immunization: a Randomized Controlled Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":537,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT00892775","title":"Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":501,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00751348","title":"Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":475,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00969436","title":"Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":450,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06667206","title":"Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT03148990","title":"Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":432,"lead_sponsor_name":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","has_results":false},{"nct_id":"NCT06331702","title":"Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":408,"lead_sponsor_name":"Liaoning Chengda Biotechnology CO., LTD","has_results":false},{"nct_id":"NCT00402831","title":"ProQuad® Intramuscular vs Subcutaneous","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":405,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05803538","title":"Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":391,"lead_sponsor_name":"Dilla University","has_results":false},{"nct_id":"NCT05279248","title":"The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Zhejiang Provincial Center for Disease Control and Prevention","has_results":false},{"nct_id":"NCT07267585","title":"Unravelling the Measles Paradox (MISIA)","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT04394689","title":"Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":281,"lead_sponsor_name":"Micron Biomedical, Inc","has_results":false},{"nct_id":"NCT03330171","title":"Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":278,"lead_sponsor_name":"University of Witwatersrand, South Africa","has_results":false},{"nct_id":"NCT05894395","title":"Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT05154097","title":"Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)","phase":"","overall_status":"UNKNOWN","enrollment_count":190,"lead_sponsor_name":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","has_results":false},{"nct_id":"NCT07356050","title":"Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease","phase":"","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}